Reports Q2 revenue $8.8M, consensus $9.77M. “We were excited to share the unprecedented efficacy of petosemtamab with pembrolizumab in first-line head and neck cancer at 2025 ASCO, and were thrilled by the response from clinicians and KOLs, which we believe continues to drive strong phase 3 site activation and support our expectation that both phase 3 trials will be substantially enrolled by year end 2025,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus (MRUS). “Additionally, I believe these data substantially enhance the likelihood of clinical success of petosemtamab. We are looking forward to providing initial clinical data on mCRC in the second half of 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus N.V.’s Phase 3 Study on Petosemtamab: A Potential Game-Changer for HNSCC Treatment
- Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study
- Truist biotech analyst holds an analyst/industry conference call
- Merus N.V.’s MCLA-129 Study: A Potential Game-Changer in Cancer Treatment
- Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know